Corcept Therapeutics

247 articles about Corcept Therapeutics

• Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

  4/22/2024

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of endogenous Cushing’s syndrome (hypercortisolism).

• Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

  4/15/2024

  Corcept Therapeutics Incorporated today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).

• Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

  4/8/2024

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

• Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

  4/1/2024

  Corcept Therapeutics Incorporated today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia.

• Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

  2/15/2024

  Corcept Therapeutics Incorporated reported its results for the quarter and year ended December 31, 2023.

• Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

  2/15/2024

  Corcept Therapeutics Incorporated announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing’s syndrome in patients with difficult-to-control type 2 diabetes.

• Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

  2/8/2024

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024.

• Corcept Appoints Roberto Vieira as President, Oncology

  1/29/2024

  Corcept Therapeutics Incorporated today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, and join the company’s Executive Team.

• Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

  1/8/2024

  Corcept Therapeutics Incorporated reported preliminary, unaudited, financial results for the quarter- and year-ended December 31, 2023, provided 2024 revenue guidance and announced a stock repurchase program.

• Corcept Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

  11/1/2023

  Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, reported results for the quarter ended September 30, 2023.

• Corcept Appoints Monica Tellado as President, Emerging Markets

  11/1/2023

  Corcept Therapeutics Incorporated announced the appointment of Monica Tellado as President, Emerging Markets.

• Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

  10/26/2023

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it has initiated MONARCH, a Phase 2b trial of its proprietary selective cortisol modulator miricorilant in patients with non-alcoholic steatohepatitis (NASH).

• Corcept Therapeutics to Announce Third Quarter 2023 Financial Results, Provide Corporate Update and Host Conference Call

  10/25/2023

  Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 1, 2023.

• Corcept Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

  8/2/2023

  Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, reported results for the quarter ended June 30, 2023.

• Corcept Therapeutics to Announce Second Quarter 2023 Financial Results, Provide Corporate Update and Host Conference Call

  7/26/2023

  Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on August 2, 2023.

• Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

  6/27/2023

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the Journal of Clinical Oncology (JCO), the premiere journal of the American Society of Clinical Oncology (ASCO).

• Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

  5/3/2023

  Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported its results for the quarter ended March 31, 2023.

• Corcept Therapeutics to Announce First Quarter 2023 Financial Results, Provide Corporate Update and Host Conference Call

  4/26/2023

  Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 3, 2023.

• Corcept Therapeutics Announces Final Results of Tender Offer

  4/5/2023

  Corcept Therapeutics Incorporated announced the final results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after 11:59 p.m., New York City time, on March 31, 2023.

• Corcept Therapeutics Announces Preliminary Results of Tender Offer

  4/3/2023

  Corcept Therapeutics announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after 11:59 p.m., New York City time, on March 31, 2023.